Sjoerd Rodenhuis - NKI / AvL

More documents

Recommendations

Info

Study Design Dutch Randomized Study N=443 F E C F E C F E C F E C F E C Start: August 1993 Closed: July 1999 (10 Dutch Centers) R N=885 RT Tamoxifen N=442 F E C F E C G‐CSF F E C F E C PBPCs CTC + PBPC‐Tx CTC: cyclophosphamide 6 g/m 2 thiotepa 480 mg/m 2 carboplatin 1600 mg/m 2 N Engl J Med 349:7‐16, 2003
N Engl J Med 349:7‐16, 2003 Recurrence‐Free Survival (all 885 Patients)
Page 1 and 2: 10 jaar Neoadjuvante Studies in het
Page 3 and 4: Verhoging van de effectiviteit van
Page 5 and 6: Verhoging van de effectiviteit van
Page 7 and 8: IHC Subtype and Pathol. CR (ddAC fo
Page 9 and 10: Neoadjuvant Response Index (NRI) NR
Page 11 and 12: NRI in 118 patients with TN Breast
Page 13 and 14: TN tumors. Initial Regimen = ddAC E
Page 15 and 16: Which Neoadjuvant Drug Regimen is B
Page 17 and 18: Identificatie van Resistentiegenen
Page 19: Genes Chromosomes Cancer 2011, 50:
Page 23 and 24: Findings in TN (Basal‐like) BC
Page 25 and 26: Neo‐TN study (Req. 270 patients)
Page 27 and 28: Lips E, Ladach N, et al., Breast Ca
Page 29 and 30: Neo‐TN study (Req. 270 patients)

Sjoerd Rodenhuis - NKI / AvL

Create successful ePaper yourself

Delete template?

Save as template?